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Abstract
Thoracic aortic aneurysm (TAA) is a genetic disease predisposing to aortic dissection. It is 
important to identify the genetic modifiers controlling penetrance and expressivity to improve 
clinical prognostication. Exome sequencing was performed in 27 subjects with syndromic or 
familial TAA presenting with extreme phenotypes (15 with severe TAA; 12 with mild or absent 
TAA). Family-based analysis of a subset of the cohort identified variants, genes, and pathways 
segregating with TAA severity among three families. A rare missense variant in ADCK4 
(p.Arg63Trp) segregated with mild TAA in each family. Genes and pathways identified in families 
were further investigated in the entire cohort using the optimal unified sequence kernel association 
test, finding significance for the gene COL15A1 (p=0.025) and the retina homeostasis pathway 
(p=0.035). Thus, we identified candidate genetic modifiers of TAA severity by exome-based study 
of extreme phenotypes, which may lead to improved risk stratification and development of new 
medical therapies.
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Introduction
Thoracic aortic aneurysm (TAA) is an aortopathy characterized by dilation of the proximal 
aorta and risk of life-threatening complications such as aortic dissection and sudden cardiac 
death. TAA accounts for at least 10,000 deaths per year in the United States.[1] When a 
diagnosis of TAA is made, the ability to predict complications of disease is limited. 
Guidelines for surgery incorporate aortic diameter, genetic diagnosis, and family history, but 
clinical prediction models are imperfect.[2,3] There is a critical need to improve methods for 
stratifying a patient's risk in order to optimize clinical decisions such as indications for aortic 
replacement surgery (ARS), medical therapy, activity restrictions, and frequency of follow 
up. Broadening the use of individual genotype data is one promising strategy to improve risk 
stratification.
TAA is clinically and genetically heterogeneous. TAA is associated with autosomal 
dominant connective tissue disorders (CTDs) including Marfan syndrome (MFS) (FBN1 
mutations), Loeys-Dietz syndrome (TGFBR1/TGFBR2), and vascular type Ehlers-Danlos 
syndrome (COL3A1).[4-6] Nonsyndromic TAA is also frequently genetic and may occur as 
autosomal dominant familial TAA, which in 15-20% of cases is associated with mutations in 
genes encoding vascular smooth muscle cell proteins such as ACTA2 and MYH11.[7] Thus 
existing knowledge of the genetic basis of TAA indicates that pathogenesis is mediated by 
extracellular matrix (ECM), TGFβ signaling, and the smooth muscle contraction.
Disease severity and the risk for complications are variable not only between individuals 
with different mutations in the same gene, but also between relatives with the same 
mutation, making prognosis challenging.[8,9] The severity of non-cardiovascular phenotypic 
features is also variable and may correlate with TAA severity.[5,10] The genetic mechanisms 
impacting the degree of TAA severity have not been established. For this study, we 
hypothesized that whole exome sequencing (WES) in subjects with extreme TAA 
phenotypes would identify genetic variants that modify TAA severity. We tested this 
hypothesis by complementary analyses using family-based and case-control approaches.
Methods
Detailed methods are available in the Online Resource Methods.
Study cohort and classification of TAA phenotypes
Subjects were prospectively enrolled from the Cincinnati Children's Hospital Medical Center 
Cardiovascular Genetics clinic from January 2012 to December 2014. This study was 
approved by the local Institutional Review Board, and all subjects gave informed consent. 
Subjects eligible for this study had syndromic or familial TAA or carried the same mutation 
as a first degree relative with confirmed TAA. Genetic rare variant analyses in this study 
were restricted to Caucasian subjects. Clinical data, including clinical genetic testing results, 
were collected by review of the electronic medical record. Subjects were defined as mutation 
positive if they had a pathogenic or likely pathogenic variant identified by clinical testing in 
one of 24 genes associated with TAA (Online Resource Table 1). Cardiovascular imaging 
was performed clinically and included echocardiography, magnetic resonance imaging 
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(MRI), or computed tomography. Published nomograms were used to calculate z-scores for 
subjects age 18 years or younger.[11] To divide the cohort into extreme phenotype groups, 
we identified two groups: severe and no/mild TAA. Severe TAA was defined by a history of 
aortic dissection, need for ARS according to guidelines [2], aortic diameter ≥ 5 cm, or z-
score ≥ +6. No/mild TAA was defined by a maximum aortic root or ascending aorta 
diameter ≤ 4.5 cm or z-score ≤ +4 and no history of dissection or ARS. The no/mild TAA 
group included mutation positive subjects without TAA (aortic diameter < 4 cm or z-score ≤ 
+2).[2,12]
WES and variant inclusion criteria
Sequencing was performed in the Cincinnati Children's Genetic Variation and Gene 
Discovery Core. After quality filtering, there were in total 176,885 variant calls (average 
6551 per subject). Rare variants were defined as variants with minor allele frequency <0.01 
or absent in public databases from the 1000 Genomes Project and the National Heart, Lung, 
and Blood Institute Grand Opportunity Exome Sequencing Project. Variants were filtered for 
those that were predicted to result in a protein change.
Family-based analysis for divergent extreme TAA phenotypes
Pairs of first degree relatives within the study cohort who were mutation positive by clinical 
genetic testing but demonstrated divergent extreme phenotypes were identified from 3 
families. For each pedigree the rare protein-changing variants unshared between first degree 
relatives with divergent phenotypes were selected. These unshared variants and genes were 
then analyzed across the pedigrees. To aid interpretation of the unshared rare variants within 
each pedigree, genes were ranked according to functional similarity to known TAA-causing 
genes using the prioritization algorithm of ToppGene (http://toppgene.cchmc.org).[13] Four 
bioinformatics damage prediction programs were also used to annotate missense variants. To 
investigate pathway-level associations, unshared gene lists for each pedigree were analyzed 
for functional enrichment of Gene Ontology terms and pathways using ToppGene.
Case-control design for rare variant association testing between extreme TAA phenotype 
groups
We utilized the optimal unified sequence kernel association test (SKAT-O) to perform 
burden and non-burden association tests using rare variants.[14] The two phenotype groups 
were defined as a dichotomous variable. Due to the limited power to test rare variants 
individually in the study cohort, collapsing (i.e. grouping) variants onto genetic regions is 
necessary. To investigate family-based findings within the overall cohort, each gene that 
segregated with TAA severity across two or more families was individually tested using 
SKAT-O in all 27 samples. The significant pathways that were identified in family-based 
ToppGene enrichment analyses were also tested in the overall cohort, excluding family 
members in which the enrichment was identified. These samples were excluded because 
SKAT-O is a non-burden test and these samples, which are by definition enriched for the 
tested pathways, would skew the model and limit the effects of the other samples in the 
cohort. In separate exploratory global analysis, all genes containing at least two variants in 
the overall cohort were tested using gene-level SKAT-O. Pathway-level associations were 
Landis et al. Page 3
J Cardiovasc Transl Res. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
also globally investigated by collapsing variants within Gene Ontology Biological Process 
(GO BP) terms.
Statistical analysis
Demographic information, clinical genetic data, additional cardiovascular characteristics, 
and overall number of autosomal rare variants, were compared between TAA extreme 
phenotype groups with 2x2 Fisher's exact test (categorical variables) or student's t-test 
(continuous variables). A p-value < 0.05 was used to define statistical significance.
In family-based variant segregation analysis, simulation was used to estimate the 
significance of observing any variant overlapping all 3 pedigrees. A detailed description of 
the simulation method is in the Online Resource Methods. For family-based functional 
enrichment analysis using ToppGene, a p-value < 0.05 after Bonferroni correction was used 
to define statistical significance.
SKAT-O analyses were performed using the statistical program R (version 3.2.1) and 
package ‘SKAT’ (version 1.21). The uniform variant weighting scheme was used. Age and 
gender were included as covariates. When investigating the targeted subset of genes and 
pathways identified in family-based analyses, a p-value < 0.05 was used to define statistical 
significance.[15] For exome wide gene-level SKAT-O, simulation was used to estimate 
significance. Details are provided in the Online Resource Methods.
Results
Genetic and cardiovascular features of cohort with extreme TAA phenotypes
Genetics evaluation—Demographic and clinical data for the 27 subjects in this study are 
shown in Table 1. Clinical genetic testing for TAA was previously performed in 26 of 27 
subjects. Overall, 20 subjects were positive for TAA-causing mutations in FBN1 (n=11), 
TGFBR1 (3), TGFBR2 (3), and ACTA2 (3) (Online Resource Table 2). A likely pathogenic 
variant in TGFB2 was incidentally identified with WES in one subject. The remaining 6 
subjects had TAA and autosomal dominant family history of TAA but no identified disease-
causing mutation through clinical testing or WES. Four of these 6 genotype-negative 
subjects were examined by a geneticist experienced in CTD evaluation while two were 
referred exclusively for genetic counseling. All 4 subjects examined were found to have 
signs of CTD, including one who met clinical criteria for MFS based on systemic features 
and TAA (Online Resource Table 3).[16] One subject without a formal examination by a 
geneticist has a brother with TAA and clinically documented signs of CTD.
Upon WES, there was no significant difference in the overall number of protein-changing 
rare variants between the severe TAA phenotype (334 ± 18 variants/subject) and no/mild 
TAA phenotype (328 ± 35) groups (P=0.55). In addition to the variants in TAA genes that 
were interpreted as pathogenic or likely pathogenic through clinical genetic testing, 13 other 
rare missense variants in TAA genes that were not classified as pathogenic or likely 
pathogenic were identified (Table 2). Population allele frequency data, bioinformatics 
predictions, and previous submissions to ClinVar were used to classify these variants in 
accordance with the 2015 guidelines set forth by the American College of Medical Genetics 
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and Genomics.[17] Most of these additional non-disease causing variants in TAA genes 
were found in mutation positive subjects. The MFAP5 or MYLK variant identified in a 
genotype-negative subject with mild TAA may be disease-causing based on strong damage 
predictions, as we have previously described.[18]
Extreme TAA phenotype groups—The severe TAA group (n=15 subjects) included 13 
with history of ARS, which was performed emergently for type A aortic dissection (4) or 
electively (9). The aortic diameter was documented to be least 5.0 cm in 7 of 8 adults 
undergoing elective ARS. Pre-operative imaging data was not available for one adult, but 
ARS was performed soon after TAA diagnosis. The one pediatric subject undergoing 
elective ARS had aortic root z-score of +9.5. The no/mild TAA group (n=12) included 6 
subjects with mild TAA and 6 who had no clinical evidence of TAA but are at risk because 
they are mutation positive and have at least one first degree relative with TAA who carries 
the same mutation. All mutation-negative subjects had at least mild TAA. None in the mild 
TAA group who carried a TGFβ receptor mutation had aortic diameter greater than 4.0 cm. 
Only one severe TAA subject and one no/mild TAA subject had clinical hypertension.
Family-based analyses of pedigrees with extreme TAA phenotypes
Identification of unshared rare variants within pedigrees—To compare subjects 
who have the same pathogenic mutation but clearly different TAA severity, 3 pairs of first 
degree relatives from each pedigree were studied (Figure 1). Pedigree I includes a 9 year old 
boy with MFS (maternally inherited FBN1 mutation; p.Cys1806Tyr) and severe aortic root 
dilation (z-score = +6.4), whose mother has no evidence of TAA at age 26. This boy's 
brother reportedly died secondary to a neonatal aortic dissection. Pedigree II includes a 
subject with a TGFBR1 mutation (p.Asn478Ser) who underwent elective ARS at age 59 
years for ascending aorta diameter of 5.1 cm. In contrast, his sister carries the mutation but 
has no evidence of TAA at age 55. Neither has findings of Loeys-Dietz syndrome or other 
CTD, leading to the diagnosis of familial TAA due to the TGFBR1 mutation. Finally, 
Pedigree III includes a subject with Loeys-Dietz syndrome (TGFBR2 mutation; 
p.Arg229Pro) resulting in aortic dissection at age 27, whose mutation positive sister only has 
evidence of mild TAA (aortic root 4 × 3.4 × 3.3 cm on cardiac MRI) at age 32. In each of 
these families the subject with severe TAA was younger or very close in age to the included 
relative with no/mild TAA.
Genes and variants associate with TAA severity across pedigrees—For each 
pedigree, a list of the rare variants that were unshared between first degree relatives was 
tabulated. The number of unshared rare variants in each pedigree were similar (Figure 2). In 
each pedigree, the subject with severe TAA had more rare variants overall and more with 
strong bioinformatics damage predictions (Online Resource Table 4). Lists of unshared rare 
variants and genes were compared between pedigrees. Those overlapping across at least 2 
pedigrees were selected for further analysis.
In total there were 50 genes with unshared rare variants overlapping across pedigrees. These 
are organized in Figure 3 to convey variant- and gene-level annotation data, including 
damage predictions and functional similarity to TAA genes based on ToppGene ranking. To 
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our knowledge, none of these genes is reported to cause TAA independently. For most 
genes, the rare variants were family specific. However, there were 6 genes (marked by 
asterisks in Figure 3) for which the identical variant was identified in at least 2 pedigrees. 
This includes a heterozygous variant in ADCK4 (c.187C>T, p.Arg63Trp) identified in 
individuals with mild TAA in all 3 pedigrees. This variant is predicted to affect function by 
all 4 bioinformatics programs. Based upon the reported minor allele frequency for this 
variant in control populations (0.005987), simulations utilizing 5000 sequencing data sets 
predict the likelihood for this occurring by chance as 0.009, strongly supporting the 
significance of this observation. Meanwhile, variants in GATA2, KLC4, THSD7B, MCL1, 
and ZNF98 overlapped at least two pedigrees. Each was identified in subjects with 
concordant TAA phenotypes (Figure 3). None of these 6 variants, including the ADCK4 
variant, was otherwise identified in the overall cohort.
In order to further investigate the significance of the 50 overlapping genes, each was tested 
for association with TAA severity in the overall cohort using SKAT-O. Among these 
prioritized genes, COL15A1 was most significantly associated with TAA severity (p=0.025). 
The COL15A1 variants (p.Phe851Leu, p.Ile1304Met) segregating with mild TAA in 
pedigrees are each predicted damaging by at least two prediction programs. The COL15A1 
variant (p.Phe851Leu) identified in Pedigree III was also identified within the overall cohort 
in a subject with mild TAA who carries a TGFB2 mutation. Thus, in total three subjects with 
mild TAA carried a rare coding variant in COL15A1.
Functional enrichment analysis identified significant pathways in families
Enrichment analysis of each pedigree's list of unshared rare variants using ToppGene 
identified 7 significant GO terms or pathways (Figure 4). Similar to our gene-level, targeted 
investigation of family-based findings in the overall cohort, we tested whether the gene sets 
identified by enrichment analysis in families could be validated in the remainder of the 
cohort using SKAT-O. Interestingly, the retina homeostasis genes that were enriched in 
Pedigree I were also significantly associated with TAA severity (p=0.035) (Online Resource 
Table 5). In contrast, variants in known TAA genes were not collectively associated with 
TAA severity using SKAT-O (p=0.54). Replication of a family-based finding within the 
overall cohort strongly supports these retina genes as candidate modifiers. Thus, our tiered 
approach identified significant candidate modifiers at the variant, gene, and pathway levels, 
as summarized in Figure 5.
Exome wide case-control analysis of extreme TAA phenotype groups
Exome wide SKAT-O identifies a candidate modifier gene and pathways—In 
addition to the targeted investigation of family-based findings, we performed exome wide 
rare variant analysis. Based on simulated data sets, the only individual gene to achieve 
exome wide empirical significance was PADI3 (p=7.5×10-4) (Online Resource Table 6). 
Simulations found 243 out of 5000 data sets (4.9%) that contained genes with p-values less 
than 7.5×10-4, supporting the significance of this finding. Three mild TAA subjects carried a 
missense PADI3 variant (rs142129409, rs144080386, rs144944758), each predicted 
damaging by all 4 programs. After collapsing variants within annotated GO BPs, the most 
significant SKAT-O pathways associated with TAA severity were endosome transport, 
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lipoprotein metabolism, apoptosis, and photoreceptor homeostasis (Table 3). Thus, exome 
wide SKAT-O analyses identify additional modifier candidate genes and pathways that may 
indirectly support family-based findings.
Discussion
Reduced penetrance and variable expression complicate the clinical management of 
syndromic and familial TAA. To test the hypothesis that genetic modifiers contribute to 
phenotype severity, we have studied subjects with extreme phenotypes using WES. TAA 
provides an opportunity to study genetic modifiers because syndromic and familial TAA are 
usually autosomal dominant conditions with reduced penetrance and reproductive fitness is 
adequate to study family members. The identification of TAA modifiers will improve 
methods for predicting the risk of progression to severe TAA or dissection and identify novel 
targets for medical therapy. Comprehensive prediction models will facilitate precise family-
specific and individual-based clinical recommendations, such as frequency of surveillance, 
activity restriction, medical therapy, and timing for ARS.
TAA features histopathological findings of collagen fibril dysregulation in the context of 
different disease-causing mutations.[19-21] Therefore, the collagen genes and pathways 
identified in this study are plausible candidate modifiers across different genetic causes of 
heritable TAA. Among these candidates, COL15A1 presented the strongest independent 
evidence of association, hypothetically related to its role in basement membrane structure or 
control of angiogenesis.[22] It is also notable that variants in COL3A1, COL5A1, and 
COL5A2 comprised 5 of the 13 variants identified in TAA genes that were not 
independently causative mutations (Table 2). Dysregulated TGFβ signaling is clearly 
associated with TAA, but, somewhat unexpectedly, annotated TGFβ signaling pathway gene 
sets were not associated with TAA severity in these analyses. This does not contradict 
established mechanisms because TGFβ signaling intersects with other signaling pathways 
and has diverse pleiotropic downstream effects that are incompletely defined but include 
ECM homeostasis. We speculate that the effects of certain heterozygous variants in 
collagen-related genes are subclinical in isolation but impact pathogenesis when combined 
with a TAA-causative mutation. This may contrast with the essential TGFβ signaling 
pathway that may be more likely to cause disease independently.
We observed compelling convergence between family-based findings and SKAT-O analyses 
for genes important for retina homeostasis. There is indirect evidence to suggest common 
mechanisms between ocular and aortic homeostasis. We have previously reported that 1) 
ocular findings may precede progression of TAA and 2) ocular findings correlate with TAA 
severity in pediatric patients.[23,10] It is interesting that two top candidate genes identified 
in this study, ADCK4 and COL15A1, are also associated with retinal disorders.[24,25] 
However, the possible association between different types of ocular abnormalities and TAA 
severity remains unclear. Detailed ocular phenotyping in heritable TAA is indicated and may 
identify clinical features useful for TAA risk prediction. Functional studies of these retina 
homeostasis genes (e.g. RP1L1) within the aorta are needed.
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Our findings also implicate genes important for energy metabolism, oxidative stress, and 
apoptosis as candidate modifiers. There is prior evidence that these pathways are associated 
with the development of TAA in diverse genetic contexts.[26-31] The protein product of 
ADCK4 is AarF Domain Containing Kinase 4, which translocates to the inner mitochondrial 
membrane to participate in the synthesis of coenzyme Q10 and electron transport.[32] 
ADCK4 is associated with autosomal recessive nephrotic syndrome but is also expressed in 
the thoracic aorta (www.gtexportal.org) and in cultured vascular smooth muscle cells derived 
directly from human ascending aorta (data not shown). Tissues and cells that have high 
energy requirements are known to be affected by mitochondrial dysfunction. Thus, the 
ADCK4 variant identified in this study may mediate aortic smooth muscle function or 
survival through mitochondrial energy metabolism and oxidative stress pathways. 
Identification of apoptosis and lipoprotein metabolic pathways in our exome wide SKAT-O 
analyses further supports a role for apoptosis and lipid metabolism pathways in TAA 
pathogenesis. Together these findings strongly warrant further investigation.
Throughout this study, we identified candidate modifiers in subjects with severe TAA (i.e. 
modifiers that worsen disease) and mild TAA (i.e. modifiers that lessen disease). For 
instance, the variant in ADCK4 segregated with mild TAA, suggesting a protective effect. 
The role of protective rare variants is relatively understudied but essential for the 
development of novel therapies.[33] Genomic analyses and functional studies must 
increasingly focus on protective genetic mechanisms. It is likely that combinations of rare 
variants interact to affect phenotype.[33] Variants within the same pathway may have 
opposing biological effects. Our observation of collagen-related variants in both severe and 
mild TAA demonstrates this complexity. These challenges are partially addressed by existing 
statistical methods such as SKAT-O, which has non-burden and epistatic variant-variant 
interaction functions. However, there remains a need to develop novel statistical and 
experimental platforms to define how specific variants interact to influence phenotype. This 
is particularly challenging for autosomal dominant diseases and will require low and high 
throughput experimental approaches.[34,35] Ultimately, these methods will define 
mechanisms by which aggregated variants correlate with specific phenotypes and clinical 
outcomes.
Limitations to this study include the small sample size. We aimed to optimize the power of 
rare variant analysis by studying subjects with extreme phenotypes and employing 
complementary family-based and case-control designs. Pathway-based analysis may 
overcome sample size limitations by reducing dimensionality while optimizing biological 
plausibility. However, this approach is dependent on existing knowledge and curation 
methods. This study cohort is genetically heterogeneous. Certain modifier genes may 
depend on the primary disease-causing genotype, but shared mechanisms, and therefore 
shared modifiers, likely exist. Our replication of family-based analysis findings in the overall 
cohort supports the latter. Nevertheless, validation of all identified candidates is needed in a 
larger cohort. Common variants and non-coding variants in regulatory regions were not 
studied but also may impact phenotype. For example, differential expression of mutant 
versus non-mutant alleles in TAA genes due to genetic variation in their regulatory regions 
could affect disease penetrance. The determinants of TAA severity are likely multifactorial, 
but the study of genetic modifiers is a first step to understanding complex multifactorial 
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etiologies, including factors impacting possible differences in TAA severity between men 
and women. Because patients were recruited in a subspecialty Cardiovascular Genetics 
clinic, there may be ascertainment bias in the cohort. Finally, TAA is a progressive condition 
and therefore phenotype assignment may change as the patient ages. We limited this 
theoretical risk by primarily studying adult-aged subjects and by comparing extreme 
phenotypes, recognizing that the study of young patients is necessary to predict early disease 
progression.
In conclusion, we have identified strong candidates for modifying TAA severity. This study 
identifies candidates consistent with existing knowledge of TAA pathogenesis as well as 
new genes and pathways suggesting novel mechanisms. Together, these hypothesis 
generating findings initiate a path toward risk stratification through genetic testing at an 
early stage of disease and identifying novel therapeutic targets.
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TGFβ transforming growth factor beta
WES whole exome sequencing
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Fig. 1. 
Three pedigrees containing first degree relatives with divergent extreme TAA phenotypes. - 
Red asterisks indicate subjects sequenced for family-based variant analyses. ARS: aortic 
replacement surgery, Asc: ascending aorta, BAV: bicuspid aortic valve, MVA: motor vehicle 
accident
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Fig. 2. 
Distribution of unshared rare variants between first degree relatives with divergent TAA 
phenotypes. - Cross-hatched areas represent the number of variants predicted to be 
damaging by 4 of 4 bioinformatics programs or frameshift, nonsense, stop loss, splice site, 
or initiation codon variants
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Fig. 3. 
Genes and specific variants overlap across pedigrees. - Variants that were unshared between 
first degree relatives were collected for each pedigree. Two genes overlapped all 3 pedigrees, 
and 14 to 18 genes overlapped any two pedigrees. These included ADCK4 for which the 
same variant was identified in subjects with mild TAA in all 3 pedigrees. Five other specific 
variants overlapped at least 2 of the 3 pedigrees (asterisks). The predicted functional impact 
of variants was stratified as high (missense variants predicted damaging in at least 4 of 4 
programs or frameshift/stop gain/splice variant) or low (missense variants predicted 
damaging in 0-3 programs or inframe insertions or deletions) and displayed by font size. The 
genes are ordered based on ToppGene ranking for similarity to TAA genes, reading from top 
to bottom and left to right within each overlap segment
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Fig. 4. 
Rare variants unshared between first degree relatives were enriched for GO and pathway 
annotations. - Pedigrees (circles) are connected to significantly enriched annotations 
(squares) by edges that pass through the genes contributing to the enrichment (hexagons). 
Genes found in severe TAA subjects are red, genes in mild TAA subjects are green, and 
genes in both severe and mild TAA subjects are gray. None of the enrichments overlapped 
multiple pedigrees, but some genes within the significant enrichments overlapped pedigrees 
as indicated by edges connecting a gene to more than one pedigree (e.g. COL15A1)
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Fig. 5. 
Identifying candidate modifiers of TAA severity: summary of study design and primary 
results. -Rare coding variants among subjects with extreme TAA phenotypes (severe vs no/
mild) were analyzed using a tiered approach. First, family-based analyses were performed 
using a subset of the cohort in families with divergent extreme phenotypes to identify 
segregation with TAA severity at the level of variant, gene, and pathway. Second, case-
control analyses were performed in the entire cohort for the family-based gene and pathway 
level findings and data simulation for variant level findings. Strong candidate modifiers of 
TAA severity were identified at each level, including a variant in ADCK4 (p.Arg63Trp), the 
gene COL15A1, and a pathway important for retina homeostasis. SKAT-O: optimal unified 
sequence kernel association test.
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Table 1
Cohort description and TAA severity groups
Entire cohort, N (%) Severe TAA (n=15) No/mild TAA (n=12) P-value
Age (y)† 29 ± 16 25 ± 15 35 ± 16 0.10
Sex 0.13
 Male 18 (67) 12 (80) 6 (50)
 Female 9 (33) 3 (20) 6 (50)
Clinical TAA genetic testing performed 26 (96) 15 (100) 11 (92) 0.44
Pathogenic mutation
 Any TAA gene 21 (78) 11 (73) 10 (83) 0.66
 FBN1 11 (41) 5 (33) 6 (50) 0.45
 TGFBR1 3 (11) 2 (13) 1 (8)
 TGFBR2 3 (11) 2 (13) 1 (8)
 TGFB2* 1 (4) 0 (0) 1 (8)
 ACTA2 3 (11) 2 (13) 1 (8)
 Unknown 6 (22) 4 (27) 2 (17)
Mitral valve prolapse 1.0
 Present 8 (30) 4 (27) 4 (33)
 Absent 19 (70) 11 (73) 8 (67)
Bicuspid aortic valve 0.6
 Present 4 (15) 3 (20) 1 (8)
 Absent 22 (81) 11 (73) 11 (92)
 Not reported 1 (4) 1 (7) 0 (0)
Variant counts†
 All variants 6551 ± 148 6560 ± 157 6541 ± 141 0.75
 Rare variants 331 ± 27 334 ± 18 328 ± 35 0.55
*
Identified with whole exome sequencing
†
Reported as mean ± standard deviation
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Table 3
Gene Ontology biological processes most associated with TAA severity using SKAT-O
Gene set No. Markers P-value Genes with variants in TAA cohort
Endosome transport 17 1.1×10-3 ABCA1, ANKRD27, DOPEY1, DOPEY2, EEA1, LYST, MON2, TOM1, 
YKT6, ZFYVE16
Regulation of neuron apoptosis 2 1.5×10-3 PCSK9, PPT1
Lipoprotein metabolic process 11 1.7×10-3 ANGPTL3, APOA4, CETP, FNTA, GPAA1, PIGV, PIGZ, PPT1, SCARF1
Photoreceptor cell maintenance 21 3.5×10-3 CDH23, CLRN1, GPR98, PCDH15, USH1C, USH2A
Peptide metabolic process 2 4.1×10-3 FURIN
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